menu
    • menu
    [{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Agreement","leadProduct":"Copper Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sentynl Therapeutics \/ Fortress Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Fortress Biotech"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Cyprium Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Copper Histidine","moa":"H2-receptor antagonists (cimetidine type)","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sentynl Therapeutics \/ Sentynl Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Sentynl Therapeutics \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sentynl Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sentynl Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sentynl Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Copper Histidine","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Sentynl Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sentynl Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sentynl Therapeutics \/ Undisclosed"}]

    Find Rare Diseases and Disorders Clinical Drug Pipeline Developments & Deals by Sentynl Therapeutics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 for Menkes Disease

                            Details : CUTX-101 is a subcutaneous injectable formulation of copper histidinate, which is being evaluated for the treatment of menkes disease.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 06, 2025

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Fortress Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sentynl Receives MHRA Authorization for NULIBRY® in MoCD Type A

                            Details : Nulibry (fosdenopterin) is the first therapy for patients in Great Britain with molybdenum cofactor deficiency Type A, an ultra-rare genetic disorder that often progresses rapidly in infants.

                            Product Name : Nulibry

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Fosdenopterin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histi...

                            Details : Under the agreement, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to CUTX-101 (copper histidinate) product candidate for the treatment of Menkes disease, to Sentynl.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cyprium Therapeutics and Sentynl Therapeutics Sign Development and Asset Purchase Agreement

                            Details : Sentynl has signed an agreement with Cyprium to contribute research funding for CUTX-101, a Copper Histidinate product candidate for the treatment of Menkes disease, and to purchase Cyprium's proprietary rights to CUTX-101.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : $20.0 million

                            February 24, 2021

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Recipient : Cyprium Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Sentynl Therapeutics

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Copper Histidinate Treatment for Menkes Disease

                            Details : Copper Histidinate is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Menkes Kinky Hair Syndrome.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 30, 2019

                            Lead Product(s) : Copper Histidine

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth